Current duration of Herceptin treatment upheld by studies

Even as Herceptin has become a hugely successful breast-cancer drug, doctors have been troubled by a nagging question that has billion-dollar implications: How long should patients be treated with it? Now the results of two closely watched studies announced Monday at a European cancer conference suggest an answer: Neither a shorter nor a longer duration of treatment is better at staving off a recurrence of cancer than the current standard of one year. Read the news article here.